CN119031914A - 贝鲁舒地尔用于治疗慢性肺同种异体移植功能障碍 - Google Patents

贝鲁舒地尔用于治疗慢性肺同种异体移植功能障碍 Download PDF

Info

Publication number
CN119031914A
CN119031914A CN202380033867.4A CN202380033867A CN119031914A CN 119031914 A CN119031914 A CN 119031914A CN 202380033867 A CN202380033867 A CN 202380033867A CN 119031914 A CN119031914 A CN 119031914A
Authority
CN
China
Prior art keywords
subject
lushu
bei
dil
lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380033867.4A
Other languages
English (en)
Chinese (zh)
Inventor
C·S·卡特勒
Z·M·德菲利普
H·T·金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kadmon Corp LLC
Original Assignee
Kadmon Corp LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kadmon Corp LLC filed Critical Kadmon Corp LLC
Publication of CN119031914A publication Critical patent/CN119031914A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380033867.4A 2022-04-19 2023-04-18 贝鲁舒地尔用于治疗慢性肺同种异体移植功能障碍 Pending CN119031914A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263332628P 2022-04-19 2022-04-19
US63/332,628 2022-04-19
US202263389444P 2022-07-15 2022-07-15
US63/389,444 2022-07-15
PCT/US2023/018952 WO2023205153A1 (en) 2022-04-19 2023-04-18 Belumosudil for treating chronic lung allograft dysfunction

Publications (1)

Publication Number Publication Date
CN119031914A true CN119031914A (zh) 2024-11-26

Family

ID=86330932

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380033867.4A Pending CN119031914A (zh) 2022-04-19 2023-04-18 贝鲁舒地尔用于治疗慢性肺同种异体移植功能障碍

Country Status (11)

Country Link
US (1) US20250255867A1 (https=)
EP (1) EP4511036A1 (https=)
JP (1) JP2025513240A (https=)
KR (1) KR20250003657A (https=)
CN (1) CN119031914A (https=)
AU (1) AU2023256541A1 (https=)
CA (1) CA3249201A1 (https=)
IL (1) IL316410A (https=)
MX (1) MX2024012802A (https=)
TW (1) TW202404602A (https=)
WO (1) WO2023205153A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL325938A (en) * 2023-07-17 2026-03-01 Kadmon Corp Llc Combination therapy including BTK inhibitor and BELUMOSUDIL

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR9465A (es) 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
CN113620933A (zh) 2012-10-05 2021-11-09 卡德门企业有限公司 Rho激酶抑制剂
US11311541B2 (en) * 2014-04-09 2022-04-26 Kadmon Corporation, Llc Treatment of GVHD

Also Published As

Publication number Publication date
WO2023205153A1 (en) 2023-10-26
JP2025513240A (ja) 2025-04-24
US20250255867A1 (en) 2025-08-14
TW202404602A (zh) 2024-02-01
AU2023256541A1 (en) 2024-12-05
CA3249201A1 (en) 2023-10-26
IL316410A (en) 2024-12-01
EP4511036A1 (en) 2025-02-26
MX2024012802A (es) 2024-11-08
KR20250003657A (ko) 2025-01-07
AU2023256541A2 (en) 2024-12-12

Similar Documents

Publication Publication Date Title
Bian et al. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials
Guler et al. Interstitial lung disease in 2020: a history of progress
CN107073114B (zh) 使用瑞利珠单抗治疗中度到重度嗜酸细胞性哮喘
ERSSON et al. Long-term oxygen therapy and quality of life in elderly patients hospitalised due to severe exacerbation of COPD. A 1 year follow-up study
WO2021183774A1 (en) Treating acute respiratory distress
CN119031914A (zh) 贝鲁舒地尔用于治疗慢性肺同种异体移植功能障碍
Contoli et al. Assessing small airway impairment in mild-to-moderate smoking asthmatic patients
JP2025106329A (ja) ベンラリズマブを使用した強化された患者個体群における慢性閉塞性肺疾患を治療するための方法
Mansour et al. Vanishing lung syndrome: a case report and systematic review of the literature
US20250352520A1 (en) Use of dexpramipexole for the treatment of eosinophilic copd
Dobler In tobacco smokers with respiratory symptoms, a dual bronchodilator did not reduce symptoms at 12 wk
Phillips et al. COVID-19 Case Complicated with Organizing Pneumonia and Pneumothorax: A Case Report
Perry Idiopathic pulmonary fibrosis: an overview.
Patil et al. Case Report with Review of Literature: Combined Pulmonary Fibrosis with Emphysema (CPFE)-Case Report
CHOWDHURY et al. Is COVID-19 masking or delayed the diagnosis of active pulmonary tuberculosis? A case report from Bangladesh
Palacios et al. An Investigational Inhaled rhIL-1Ra (ALTA-2530) Demonstrates Distribution to Distal Regions of Lung and High Affinity IL-1 Receptor Blockade Supporting Development as a Treatment for Bronchiolitis Obliterans Syndrome
Sherpa et al. A Rare Case of Anomalous Origin of Right Pulmonary Artery with PDA and Features of Eisenmenger Syndrome in 40-Year-Old Nepalese Male
Hossain et al. Modified D2 Gastrectomy operation in Gastric Cancer Patients and Outcome
배주예 Risk factors of acute exacerbation and disease progression in young patients with COPD
Kulaksız et al. Analysis of the patients admitted to our emergency department due to chronic obstructive pulmonary disease exacerbation.
Jung et al. The change of lung function in children with bronchiolitis obliterans syndrome after hematopoietic stem cell transplant
Prikhodko et al. Asthma-chronic obstructive pulmonary disease overlap syndrome
Sasank Decaf Score in Predicting Prognosis of Acute Exacerbation of Copd
Kwon et al. A 64-Year-Old Man With Rapidly Progressive Respiratory Failure and Pneumomediastinum
Dron et al. Effect of l-arginine on life quality in patients with hypertensive disease and chronic obstructive pulmonary disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination